The prescription patterns and adherence of disease-modifying drugs for Multiple Sclerosis in Saskatchewan 1997-2013

Background: The disease modifying drugs (DMDs) for Multiple Sclerosis were approved as a benefit by the Provincial Drug Plan under Exception Drug Status, Department of Health, Saskatchewan, in November 1997. It is estimated that thirty to forty percent discontinue treatment within two years. The obj...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Canadian journal of neurological sciences 2014-05, Vol.41 (3), p.S29-S29
Hauptverfasser: Hader, W J, Knox, K B
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S29
container_issue 3
container_start_page S29
container_title Canadian journal of neurological sciences
container_volume 41
creator Hader, W J
Knox, K B
description Background: The disease modifying drugs (DMDs) for Multiple Sclerosis were approved as a benefit by the Provincial Drug Plan under Exception Drug Status, Department of Health, Saskatchewan, in November 1997. It is estimated that thirty to forty percent discontinue treatment within two years. The objective is to compare the prescription patterns and adherence of four approved DMD's. Methods: A prospective database and cohort analysis of all applications eligible for drug prescriptions was maintained 16 years. Descriptive analysis was performed after November 15th 2013 using SPSS v21. Results: There were 1565 eligible prescriptions, including Avonex 168 (10.7%), Betaseron 355 (22.7%), Copaxone 723 (46.2%), and Rebif 318 (20.3%). 1409 (90%) started a dmg. Currently 546 (34.9%) remain on the initial prescription including Avonex 52 (30.9%), Betaseron 83 (23.4%), Copaxone 293 (40.5%), and Rebif 118 (37.1%), the latter two drugs showing a higher adherence rate. 863 discontinued and 156 never started. 565 persons were prescribed 2-5 drugs. 796 (50.9%) continue treatment including 250 persons who switched. Conclusions: The adherence on DMD treatments is low, even after changing treatments. Further study is warranted to understand the factors which impact drug utilization in Multiple Sclerosis.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1654684390</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1654684390</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_16546843903</originalsourceid><addsrcrecordid>eNqVyrFuwjAQAFAPrVRo-w83dolkk-CQGVGxMMGOTvaFXDG28TlC_XuW_kCnt7wXtdCt6Rtje_OmliI_Wq_s2nYLJaeJIBcSVzhXThEy1kolCmD0gH6iQtERpBE8C6FQc0uex1-OF_BlvgiMqcBhDpVzIDi6QCUJC3CEI8oVq5vogRHMMPTNSpv2Q72OGIQ-_3xXX9-703bf5JLuM0k931gchYCR0ixnY9ed3XTtoNt_1CdKQk6P</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1654684390</pqid></control><display><type>article</type><title>The prescription patterns and adherence of disease-modifying drugs for Multiple Sclerosis in Saskatchewan 1997-2013</title><source>Cambridge University Press Journals Complete</source><creator>Hader, W J ; Knox, K B</creator><creatorcontrib>Hader, W J ; Knox, K B</creatorcontrib><description>Background: The disease modifying drugs (DMDs) for Multiple Sclerosis were approved as a benefit by the Provincial Drug Plan under Exception Drug Status, Department of Health, Saskatchewan, in November 1997. It is estimated that thirty to forty percent discontinue treatment within two years. The objective is to compare the prescription patterns and adherence of four approved DMD's. Methods: A prospective database and cohort analysis of all applications eligible for drug prescriptions was maintained 16 years. Descriptive analysis was performed after November 15th 2013 using SPSS v21. Results: There were 1565 eligible prescriptions, including Avonex 168 (10.7%), Betaseron 355 (22.7%), Copaxone 723 (46.2%), and Rebif 318 (20.3%). 1409 (90%) started a dmg. Currently 546 (34.9%) remain on the initial prescription including Avonex 52 (30.9%), Betaseron 83 (23.4%), Copaxone 293 (40.5%), and Rebif 118 (37.1%), the latter two drugs showing a higher adherence rate. 863 discontinued and 156 never started. 565 persons were prescribed 2-5 drugs. 796 (50.9%) continue treatment including 250 persons who switched. Conclusions: The adherence on DMD treatments is low, even after changing treatments. Further study is warranted to understand the factors which impact drug utilization in Multiple Sclerosis.</description><identifier>ISSN: 0317-1671</identifier><language>eng</language><ispartof>Canadian journal of neurological sciences, 2014-05, Vol.41 (3), p.S29-S29</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Hader, W J</creatorcontrib><creatorcontrib>Knox, K B</creatorcontrib><title>The prescription patterns and adherence of disease-modifying drugs for Multiple Sclerosis in Saskatchewan 1997-2013</title><title>Canadian journal of neurological sciences</title><description>Background: The disease modifying drugs (DMDs) for Multiple Sclerosis were approved as a benefit by the Provincial Drug Plan under Exception Drug Status, Department of Health, Saskatchewan, in November 1997. It is estimated that thirty to forty percent discontinue treatment within two years. The objective is to compare the prescription patterns and adherence of four approved DMD's. Methods: A prospective database and cohort analysis of all applications eligible for drug prescriptions was maintained 16 years. Descriptive analysis was performed after November 15th 2013 using SPSS v21. Results: There were 1565 eligible prescriptions, including Avonex 168 (10.7%), Betaseron 355 (22.7%), Copaxone 723 (46.2%), and Rebif 318 (20.3%). 1409 (90%) started a dmg. Currently 546 (34.9%) remain on the initial prescription including Avonex 52 (30.9%), Betaseron 83 (23.4%), Copaxone 293 (40.5%), and Rebif 118 (37.1%), the latter two drugs showing a higher adherence rate. 863 discontinued and 156 never started. 565 persons were prescribed 2-5 drugs. 796 (50.9%) continue treatment including 250 persons who switched. Conclusions: The adherence on DMD treatments is low, even after changing treatments. Further study is warranted to understand the factors which impact drug utilization in Multiple Sclerosis.</description><issn>0317-1671</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqVyrFuwjAQAFAPrVRo-w83dolkk-CQGVGxMMGOTvaFXDG28TlC_XuW_kCnt7wXtdCt6Rtje_OmliI_Wq_s2nYLJaeJIBcSVzhXThEy1kolCmD0gH6iQtERpBE8C6FQc0uex1-OF_BlvgiMqcBhDpVzIDi6QCUJC3CEI8oVq5vogRHMMPTNSpv2Q72OGIQ-_3xXX9-703bf5JLuM0k931gchYCR0ixnY9ed3XTtoNt_1CdKQk6P</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Hader, W J</creator><creator>Knox, K B</creator><scope>7TK</scope></search><sort><creationdate>20140501</creationdate><title>The prescription patterns and adherence of disease-modifying drugs for Multiple Sclerosis in Saskatchewan 1997-2013</title><author>Hader, W J ; Knox, K B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_16546843903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hader, W J</creatorcontrib><creatorcontrib>Knox, K B</creatorcontrib><collection>Neurosciences Abstracts</collection><jtitle>Canadian journal of neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hader, W J</au><au>Knox, K B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The prescription patterns and adherence of disease-modifying drugs for Multiple Sclerosis in Saskatchewan 1997-2013</atitle><jtitle>Canadian journal of neurological sciences</jtitle><date>2014-05-01</date><risdate>2014</risdate><volume>41</volume><issue>3</issue><spage>S29</spage><epage>S29</epage><pages>S29-S29</pages><issn>0317-1671</issn><abstract>Background: The disease modifying drugs (DMDs) for Multiple Sclerosis were approved as a benefit by the Provincial Drug Plan under Exception Drug Status, Department of Health, Saskatchewan, in November 1997. It is estimated that thirty to forty percent discontinue treatment within two years. The objective is to compare the prescription patterns and adherence of four approved DMD's. Methods: A prospective database and cohort analysis of all applications eligible for drug prescriptions was maintained 16 years. Descriptive analysis was performed after November 15th 2013 using SPSS v21. Results: There were 1565 eligible prescriptions, including Avonex 168 (10.7%), Betaseron 355 (22.7%), Copaxone 723 (46.2%), and Rebif 318 (20.3%). 1409 (90%) started a dmg. Currently 546 (34.9%) remain on the initial prescription including Avonex 52 (30.9%), Betaseron 83 (23.4%), Copaxone 293 (40.5%), and Rebif 118 (37.1%), the latter two drugs showing a higher adherence rate. 863 discontinued and 156 never started. 565 persons were prescribed 2-5 drugs. 796 (50.9%) continue treatment including 250 persons who switched. Conclusions: The adherence on DMD treatments is low, even after changing treatments. Further study is warranted to understand the factors which impact drug utilization in Multiple Sclerosis.</abstract></addata></record>
fulltext fulltext
identifier ISSN: 0317-1671
ispartof Canadian journal of neurological sciences, 2014-05, Vol.41 (3), p.S29-S29
issn 0317-1671
language eng
recordid cdi_proquest_miscellaneous_1654684390
source Cambridge University Press Journals Complete
title The prescription patterns and adherence of disease-modifying drugs for Multiple Sclerosis in Saskatchewan 1997-2013
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T04%3A58%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20prescription%20patterns%20and%20adherence%20of%20disease-modifying%20drugs%20for%20Multiple%20Sclerosis%20in%20Saskatchewan%201997-2013&rft.jtitle=Canadian%20journal%20of%20neurological%20sciences&rft.au=Hader,%20W%20J&rft.date=2014-05-01&rft.volume=41&rft.issue=3&rft.spage=S29&rft.epage=S29&rft.pages=S29-S29&rft.issn=0317-1671&rft_id=info:doi/&rft_dat=%3Cproquest%3E1654684390%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1654684390&rft_id=info:pmid/&rfr_iscdi=true